ADGEN   is   using   its   patented   technologies   as   an   umbrella under   which   it is   developping   a   series   of   chemical   analogs   based   on   the   structures   of   our lead   lipid   mobiliser   protein,   as   well   as   novel   phospho-tau   inhibitor   compounds.   The   lead   optimization   process   will   result   in   the   production   of   new chemical   entities   (NCEs)   for pre-clinical   research   programs.   The   final   candidates   which   are   bound   to   be   very   similar   in   structure   to our   key   lead compounds   are designed   to   improve   on   their   current   regenerative   or   inhibiting   properties,   brain   penetration   and   cardiovascular   safety   profile.   The production   of   potent   apoloproteins   modulators   that   stimulates   brain   reinnervation   will   be   used   to   slow   down   or,   possibly   stop   disease   progression, but   more   importantly,   to   delay   the   onset   of   the   disease   in   people   who   are   not   symptomatic   but   carry   defective   “at   risk”   genes.   This   represents   a clear   practical   and   achievable   mid-term   goal.   It   has   been   determined   that a   five   years   delay   in   the   onset   of   AD   could   translate   into   a   reduction   of the   prevalence   of Alzheimer's   disease   by   50%   in   occidental   countries   over   one   generation   and   in   a   reduction   of caring   cost   (direct   and   indirect)   in excess   of   $1000 billions   worldwide (in   2018   dollars).   The   worldwide   market   for   such   a   drug   in   Alzheimer's   disease   alone   is   estimated   to   be   in   the order of $12-15 billion per year. ADGEN   has   identified   several   novel   genetic   and   proteomic   markers   for   age   of   onset,   disease   progression   and   response   to   standard   therapies   in neurodegenerative   diseases   and   stroke,   all   linked   to   the   neuronal   remodeling   pathways.   The ADGEN   team   has   also   discovered   protective   genetic variants   that   attenuate   risk   and   affect   age   of   onset   while   providing   interesting   new   therapeutic   targets.   Dr.   Poirier’s   research   team   has   carried   out extensive   pharmacogenomic   programs   the   past   three   decades   with   international   pharmas,   including   Warner-Lambert,   Pfizer,   Novartis,   Avantis, Servier,   Astrazeneca    and    Bayer,    principallly    on cognitive    enhancer drugs    exhibiting    different    modes    of    action.    These    programs    have    been associated   with   compound   drug   development   where   a   focus   was   built   around   individual   response   to   specific   therapeutic   agents. This   approach   has aided   the   interpretation   of   marginal   drug   effects   and   established   a   molecular   basis   for   efficacy   and   safety   in   several   experimental   compounds   in randomised,   double-blind,   clinical   trials.   Dr.   Poirier   has   also   worked   with   the   genomic   team   at   Motorola   on   experimental   devices   designed   to perform   low-cost   genetic   profiles   to   be   used   in   physician   offices,   an   emerging   market   for   both,   the   US   and   Europe.   The   initial   research-business concept   holds   true   today,   but   in   a   broader   sense. The ADGEN   team   has   a   well   documented   and   proprietary   knowledge   of   mechanisms   for   neuronal remodeling through the study of neuron degeneration caused by neurodegenerative diseases or trauma.
Services
© J. Poirier 2022
Franšais Franšais
Français
Français